Using the Chicken Chorioallantoic Membrane In Vivo Model to Study Gynecological and Urological Cancers
January 28th, 2020
10K views
We present the chicken chorioallantoic membrane model as an alternative, transplantable, in vivo model for the engraftment of gynecological and urological cancer cell lines and patient-derived tumors.
Overview
The chicken chorioallantoic membrane (CAM) model serves as a transplantable, in vivo system for studying gynecological and urological cancer cell lines and patient-derived tumors. This method allows for rapid tumor growth in an immunotolerant environment, facilitating the testing of novel therapeutic approaches.
Key Study Components
Area of Science
- Oncology
- Transplantation Biology
- In Vivo Models
Background
- The CAM model is a cost-effective alternative for tumor engraftment.
- It supports studies on tumorigenicity and treatment efficacy.
- The model is immunotolerant, allowing for human tumor studies.
- Proper CAM formation is crucial for successful engraftment.
Purpose of Study
- To present the CAM model as a viable option for cancer research.
- To enable rapid testing of therapeutic strategies.
- To facilitate the study of cellular interactions in tumors.
Methods Used
- Engrafting tumors onto the CAM of chicken embryos.
- Identifying blood vessel networks for optimal tumor placement.
- Monitoring tumor growth and response to treatments.
- Utilizing patient-derived tumor specimens in experiments.
Main Results
- The CAM model allows for effective tumor engraftment.
- Rapid tumor growth was observed in the immunotolerant setting.
- Novel therapeutic approaches can be tested efficiently.
- Proper handling of the CAM is essential for successful outcomes.
Conclusions
- The CAM model is a promising tool for cancer research.
- It provides a platform for studying treatment efficacy.
- Future studies can leverage this model for innovative therapies.
Frequently Asked Questions
What is the chicken chorioallantoic membrane model?
It is an in vivo model used for engrafting tumors to study cancer biology.
Why is the CAM model considered immunotolerant?
The CAM allows for human tumor growth without rejection by the host.
What types of tumors can be studied using the CAM model?
Gynecological and urological cancer cell lines and patient-derived tumors.
How does the CAM model facilitate rapid testing of therapies?
It allows for quick tumor growth and assessment of treatment responses.
What are the critical steps in preparing the CAM for tumor engraftment?
Ensuring proper CAM formation and careful handling to avoid damage.
Can patient tumor specimens be used in the CAM model?
Yes, the model supports the use of patient-derived tumor specimens.
Executive Industry Relevance
The chicken chorioallantoic membrane (CAM) model offers a cost-effective, rapid in vivo system for studying gynecological and urological cancers, enabling early-stage therapeutic testing without the need for immunocompromised murine models. Its immunotolerant nature supports engraftment of human and murine tumor specimens, facilitating preclinical de-risking of novel compounds. This model accelerates discovery timelines by allowing direct visualization and bioluminescence imaging of tumor growth, invasion, and therapeutic response within days.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumorigenicity and metastatic potential in a vascularized in vivo environment.
- Operational Value: Supports rapid assessment of therapeutic efficacy using bioluminescence imaging for sensitive tumor detection.
- Strategic Value: Reduces reliance on murine models, lowering cost and timelines for target validation in oncology pipelines.
Screening & Assay Development
- Scientific Value: Provides a reproducible platform for engrafting diverse tumor types, including cell lines and primary tissues.
- Operational Value: Standardizes tumor implantation procedures through defined extracellular matrix and medium formulations.
- Strategic Value: Enables scalable screening of therapeutic candidates using standardized implantation and imaging protocols.
Translational & Preclinical Research
- Scientific Value: Facilitates study of tumor-stromal interactions and therapeutic response in a disease-relevant in vivo context.
- Operational Value: Allows longitudinal monitoring of tumor growth and metastasis via non-invasive imaging.
- Strategic Value: Supports go/no-go decisions by providing predictive data on drug efficacy and toxicity in a whole-organism setting.
Pipeline & Workflow Integration
The CAM model integrates into early discovery workflows as a bridge between in vitro screening and murine preclinical studies, offering a rapid, cost-effective in vivo validation step for gynecological and urological cancer targets.
- Discovery Biology: Supports hypothesis testing of tumor growth, invasion, and metastasis in a vascularized, immunotolerant environment.
- Screening: Enables standardized, reproducible tumor engraftment for consistent compound evaluation across laboratories.
- Analytics: Generates quantitative bioluminescence readouts to assess tumor burden and treatment response over time.
- Translational Research: Provides continuity from cell line validation to preclinical testing by modeling human tumor engraftment without genetic modification.
- Enterprise Reuse: Functions as a reusable platform for multiple cancer types and therapeutic modalities within oncology portfolios.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by modeling tumor growth in a physiologically relevant, vascularized in vivo system.
- Operational Value: Reduces time and resource expenditure compared to murine models, with tumor assessment possible within 14 days post-engraftment.
- Strategic Value: Improves capital efficiency by enabling early de-risking of therapeutic candidates before costly murine studies.
- Portfolio Impact: Supports risk-adjusted prioritization of oncology projects through rapid, in vivo efficacy data.
Implementation Considerations
- Requires expertise in embryological techniques and sterile handling of chicken embryos.
- Dependent on specialized instrumentation including egg candlers, rotary tools, and forceps for membrane manipulation.
- Necessitates standardized protocols for tumor suspension preparation and extracellular matrix mixing to ensure engraftment consistency.
- Requires adaptation across tumor types due to variable engraftment efficiency observed in ovarian, renal, prostate, and bladder cancers.
- Limited by the short developmental window of chicken embryos, restricting studies to approximately two weeks post-engraftment.
Biopharma FAQs
Why does bioluminescence imaging matter for tumor detection in the CAM model?
Bioluminescence imaging enables sensitive detection of tumor growth and metastasis in the CAM model, particularly for weakly tumorigenic cancers like ovarian cancer that may not be visible otherwise. This allows longitudinal monitoring of therapeutic response without sacrificing embryos. The method supports quantitative assessment of treatment efficacy in preclinical oncology studies.
How does extracellular matrix supplementation support tumor engraftment in the CAM model?
Tumor cells are resuspended in medium supplemented with extracellular matrix (2.7–4 mg/mL) to prevent cellular dispersal and provide nutrient support until vascular recruitment occurs. This formulation maintains cell viability and promotes localized engraftment at the implantation site. Proper matrix preparation is critical for successful tumor establishment in the CAM.
What vascular features are optimal for tumor implantation in the CAM model?
Ideal implantation sites feature a large blood vessel with smaller branching vessels near the center of the opened CAM area, particularly at branch points. These locations support robust nutrient delivery and vascular integration of engrafted tumor cells. The protocol emphasizes targeting well-developed vasculature to enhance tumor take and growth.
Why does replication matter for cross-functional collaboration in CAM-based studies?
Replication ensures consistent tumor engraftment and growth across embryos, enabling reliable data sharing between discovery, screening, and preclinical teams. Standardized outcomes reduce variability in therapeutic response assessments. This supports aligned decision-making across functions in oncology drug development pipelines.
What statistical analysis is required before implementing the CAM model in therapeutic screening?
Implementation requires analysis of tumor engraftment efficiency, growth kinetics, and bioluminescence signal variability across replicates to define meaningful effect sizes. Thresholds for tumor take rates and signal-to-noise ratios must be established to ensure assay robustness. These analyses inform go/no-go criteria for therapeutic candidates in early discovery workflows.
